2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123567
    LY86057 148966-66-9 98%
    LY86057 is an ergoline derivative without N1 substituents. It has higher affinity for porcine, squirrel monkey and human 5-HT2 receptors than rats and is an antagonist of 5-HT2 receptors. When studying the differences in recognition of a series of ergolines between species, LY86057 was found to be more selective for 5-HT2 receptors. Compared with LY53857, LY108742 resulted in a higher affinity for rat 5-HT2 receptors even when the N1 substituent was only methyl.
    LY86057
  • HY-123594
    R-2 Methanandamide 157182-47-3 98%
    R-2 Methanandamide (Compound 2) is a cannabinoid Anandamide (HY-10863) analog with a Ki of 119 nM for the cannabinoid receptor (Ki is determined using rat brain membranes with PMSF).
    R-2 Methanandamide
  • HY-123654
    L-796449 194608-80-5 98%
    L-796449 is a potent PPARγ agonist. L-796449 shows neuroprotective. L-796449 has the potential for the research of stroke.
    L-796449
  • HY-123655
    Fenazinel dihydrochloride 685138-02-7 98%
    Fenazinel dihydrochloride, an N-methyl-D-aspartate (NMDA) receptor antagonist, shows promise as a potential treatment for ischemic stroke.
    Fenazinel dihydrochloride
  • HY-123661
    MIPS1455 1627580-82-8 98%
    MIPS1455 is a light-activated M1 muscarinic acetylcholine receptor ligand with irreversible binding activity to the allosteric site of the receptor. MIPS1455 is a drug target under investigation for the suppression of cognitive deficits and may become a valuable molecular tool for further investigation of allosteric interactions of the receptor.
    MIPS1455
  • HY-123677
    E2508 685886-34-4 98%
    E2508 is an orally active corticotropin-releasing factor 1 (CRF1) receptor antagonist with a Ki value of 11 nM for hCRF1.
    E2508
  • HY-123704
    CGS-12066 maleate 1350965-83-1 98%
    CGS-12066 (maleate) is a 5-HT receptor agonist. CGS-12066 has agonist effect for 5-HT1A , 5-HT1B ,5-HT1C and 5-HT1D with pEC50 values of 6.41, 7.56, 4.05 and 7.11, respectively. CGS-12066 can be used for the research of neurological disease.
    CGS-12066 maleate
  • HY-123743
    JNJ-42314415 1334165-90-0 98%
    JNJ-42314415 is a centrally active phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 35 nM and 64 nM for human recombinant PDE10A and rPDE10A, respectively.
    JNJ-42314415
  • HY-12383S
    Pelubiprofen-13C,d3 98%
    Pelubiprofen-13C,d3 is the 13C- and deuterium labeled Pelubiprofen. Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on COX-2 activity. Pelubiprofen inhibits COX activity and the transforming growth factor-β activated kinase 1-IκB kinase β-NF-κB pathway, and has significant anti-inflammatory and analgesic effects.
    Pelubiprofen-13C,d3
  • HY-123840
    MRK-623 461449-78-5 98%
    MRK-623 (Compound 14k) is an orally active, high-affinity GABAA receptor agonist, with the Ki values of 0.85 nM, 3.7 nM, 4.0 nM, and 0.53 nM for α1, α2, α3, and α5, respectively. MRK-623 shows anxiolytic effect.
    MRK-623
  • HY-123869
    GR127935 148672-13-3 98%
    GR127935 is a selective 5-HT1D receptor antagonist. GR127935 can be used for neurological research.
    GR127935
  • HY-12390A
    Lofepramine hydrochloride 26786-32-3 98%
    Lofepramine (Lopramine) is a modified tricyclic and orally active antidepressant. Lofepramine inhibits the uptake of Noradrenaline (NA) (HY-13715) and 5-hydroxytryptamine (5-HT) with IC50s of 2.7 μM and 11 μM, respectively. Lofepramine exerts its antidepressant activity by promoting noradrenergic neurotransmission. Lofepramine also enhances serotonergic neurotransmission by inhibiting neuronal uptake of 5-HT and tryptophan pyrrolase. Lofepramine exhibits significant anxiolytic properties. .
    Lofepramine hydrochloride
  • HY-124015
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one 177987-23-4 98%
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one (Compound 1) is an inhibitor of oleamide hydrolase.
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one
  • HY-124019
    4,5-DiHDPA lactone 845673-68-9 98%
    4,5-DiHDPA lactone (5), a derivative of docosahexaenoic acid (DHA), is a PPARγ activator.
    4,5-DiHDPA lactone
  • HY-124030
    3-Hydroxyphenazepam 70030-11-4 98%
    3-Hydroxyphenazepam is an active metabolite of Cinazepam. Cinazepam is a GABAA receptor agonist. 3-Hydroxyphenazepam can inhibit synaptosomal transporter-mediated [3H]GABA uptake.
    3-Hydroxyphenazepam
  • HY-124047
    RX 67668 40709-76-0 98%
    RX 67668 is a potent cholinesterase inhibitor with an IC50 of 5 μM for both acetylcholinesterase (AChE) and butyrylcholinesterase. RX 67668 can reverse the neuromuscular blockade induced by D-tubocurarine. RX 67668 is a muscle relaxant used to relieve skeletal muscle fatigue.
    RX 67668
  • HY-124086
    BHQ-O-5HT 1417436-52-2 98%
    BHQ-O-5HT is a light-activated caged 5-HT protected by a BHQ group. When exposed to light at 365 or 740 nm, BHQ-O-5HT releases 5-HT through 1 or 2 photon excitation, respectively. BHQ-O-5HT can be manipulated in space and time to explore the role of 5-HT in regulating mood, appetite, memory, learning, and other cognitive functions.
    BHQ-O-5HT
  • HY-124109
    TRC051384 hydrochloride 1333327-56-2 98%
    TRC051384 hydrochloride is a potent inducer of heat shock protein 70 (HSP70). TRC051384 hydrochloride exhibits protective effects against neuronal trauma via inhibition of necroptosis. TRC051384 hydrochloride can be used for the research of ischemic stroke.
    TRC051384 hydrochloride
  • HY-124110
    TC299423 1975146-56-5 98%
    TC299423 is an orally active, brain-penetrant, selective and potent agonist for α6β2? and α4β2? nicotinic acetylcholine receptors (nAChRs) with anxiolytic and antinociceptive properties. TC299423 acts primarily through α6β2? nAChRs that are implicated in the anxiolytic effects of nicotine. TC299423 elicits reward-related behavior mediated through α6β2? nAChRs in hypersensitive α6L90’S mice. TC299423 elicits dopamine release and dose not suppress nicotine self-administration in rats. TC299423 is proming for rasearch of addiction and Parkinson’s disease.
    TC299423
  • HY-124117
    LY 278584 119193-37-2
    LY 278584 is a potent, highly selective 5-HT3 receptor antagonist with a Ki of 1.62 nM. LY 278584 has no activity on 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, or 5-HT2 receptors.
    LY 278584
Cat. No. Product Name / Synonyms Application Reactivity